Literature DB >> 3087462

Prevalence of hepatitis B virus infection among black children in Soweto.

A M Dibisceglie, M C Kew, G M Dusheiko, E L Berger, E Song, A C Paterson, H J Hodkinson.   

Abstract

Roughly 15% of black children in rural areas of southern Africa are carriers of the hepatitis B virus. The purpose of the present study was to determine the prevalence of chronic hepatitis B virus infection among urban black children born and growing up in Soweto. A total of 2364 children were studied, ranging in age from 3 to 19 years, and of these, 1319 (56%) were girls. The children were drawn from the highest and the lowest socioeconomic classes. Serum samples were tested for all hepatitis B virus markers as well as IgG antibody against hepatitis A virus. HBsAg was detected in 23 (0.97%) of the children, anti-HBc and anti-HBs together in 155 (6.6%), anti-HBc alone in 17 (0.7%), and anti-HBs alone in 72 (3%). Of the 2364 children, 2097 (88.5%) were negative for all hepatitis B virus markers. IgG antibody to hepatitis A virus was present in 175 (97%) of a sample of 179 children. There was no difference in prevalence of hepatitis B virus markers between children from the upper and lower socioeconomic classes. HBsAg was more common in boys (16 out of 1043 (1.5%) than girls (seven out of 1321 (0.57%), and the prevalence of all hepatitis B virus markers increased with age. The youngest carrier of hepatitis B virus was 7 years old. The remarkable difference in the hepatitis B virus carrier rate between urban and rural black children offers a unique opportunity to investigate the favourable influences operating in an urban environment to limit the prevalence of hepatitis B virus infection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3087462      PMCID: PMC1340439          DOI: 10.1136/bmj.292.6533.1440

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  13 in total

1.  Role of arthropods in transmission of hepatitis-B virus in the tropics.

Authors:  B Brotman; A M Prince; H R Godfrey
Journal:  Lancet       Date:  1973-06-09       Impact factor: 79.321

2.  The epidemiology of serum hepatitis (SH) infections: a controlled study in two closed institutions.

Authors:  W Szmuness; A M Prince
Journal:  Am J Epidemiol       Date:  1971-12       Impact factor: 4.897

Review 3.  Hepatocellular carcinoma and hepatitis B virus.

Authors:  R P Beasley; L Y Hwang
Journal:  Semin Liver Dis       Date:  1984-05       Impact factor: 6.115

Review 4.  Transmission of hepatitis B virus.

Authors:  D P Francis; M S Favero; J E Maynard
Journal:  Semin Liver Dis       Date:  1981-02       Impact factor: 6.115

5.  Hepatitis B surface antigen carrier state in hepatosplenic schistosomiasis.

Authors:  L G Lyra; G Rebouças; Z A Andrade
Journal:  Gastroenterology       Date:  1976-10       Impact factor: 22.682

6.  Hepatitis B virus carrier state in black children in Ovamboland: role of perinatal and horizontal infection.

Authors:  J F Botha; M J Ritchie; G M Dusheiko; H W Mouton; M C Kew
Journal:  Lancet       Date:  1984-06-02       Impact factor: 79.321

7.  Spontaneous reactivation of chronic hepatitis B virus infection.

Authors:  G L Davis; J H Hoofnagle; J G Waggoner
Journal:  Gastroenterology       Date:  1984-02       Impact factor: 22.682

8.  Immune responses to hepatitis B virus and tuberculosis infections in Southeast Asian refugees.

Authors:  K A McGlynn; E D Lustbader; W T London
Journal:  Am J Epidemiol       Date:  1985-12       Impact factor: 4.897

9.  Incidence of hepatitis B virus infections in preschool children in Taiwan.

Authors:  R P Beasley; L Y Hwang; C C Lin; M L Leu; C E Stevens; W Szmuness; K P Chen
Journal:  J Infect Dis       Date:  1982-08       Impact factor: 5.226

10.  Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis.

Authors:  J H Hoofnagle; G M Dusheiko; L B Seeff; E A Jones; J G Waggoner; Z B Bales
Journal:  Ann Intern Med       Date:  1981-06       Impact factor: 25.391

View more
  8 in total

1.  Prevalence of hepatitis B and hepatitis C coinfections in an adult HIV centre population in Gaborone, Botswana.

Authors:  Premal Patel; Stephanie Davis; Michael Tolle; Vincent Mabikwa; Gabriel Anabwani
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

Review 2.  The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa.

Authors:  C F Kiire
Journal:  Gut       Date:  1996       Impact factor: 23.059

3.  Hepatocellular carcinoma in urban born blacks: frequency and relation to hepatitis B virus infection.

Authors:  M C Kew; C Kassianides; J Hodkinson; A Coppin; A C Paterson
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-22

Review 4.  HIV-HBV coinfection among South African patients receiving antiretroviral therapy.

Authors:  Adrian M Di Bisceglie; Mhairi Maskew; Doreen Schulze; Anne Reyneke; Lynne McNamara; Cindy Firnhaber
Journal:  Antivir Ther       Date:  2010

5.  The prevalence of hepatitis B co-infection in a South African urban government HIV clinic.

Authors:  Cynthia Firnhaber; Anne Reyneke; Doreen Schulze; Babatyi Malope; Mhairi Maskew; Patrick MacPhail; Ian Sanne; Adrian Di Bisceglie
Journal:  S Afr Med J       Date:  2008-07

Review 6.  Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa.

Authors:  M C Kew
Journal:  Gut       Date:  1996       Impact factor: 23.059

7.  Hepatitis B virus / human immunodeficiency virus co-infection and its hepatocarcinogenic potential in sub-saharan black africans.

Authors:  Michael C Kew
Journal:  Hepat Mon       Date:  2012-10-30       Impact factor: 0.660

8.  Hepatitis B sero-prevalence in children under 15 years of age in South Africa using residual samples from community-based febrile rash surveillance.

Authors:  Nishi Prabdial-Sing; Lillian Makhathini; Sheilagh Brigitte Smit; Morubula Jack Manamela; Nkengafac Villyen Motaze; Cheryl Cohen; Melinda Shelley Suchard
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.